
Pursuant to section 5(3)(b) of the COVID-19 Public Health Response Act 2020, I, Dr Ashley Bloomfield, Director-General of Health, hereby declare that the doses of each COVID-19 vaccine or combination of COVID-19 vaccines specified in this notice are required for a person to be “vaccinated” for the purposes of clause 13 of the COVID-19 Public Health Response (Air Border) Order 2021 ("Order"). A combination of vaccine doses will meet the definition where this is the accepted schedule in the place of vaccination.

For the purposes of clause 13 of the Order vaccinated means being vaccinated against COVID-19 with at least one of the following complete vaccination courses (meaning the combination of COVID-19 vaccine and number of doses in each line):

- Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2) 2 doses.
- AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19) 2 doses.
- AstraZeneca (Covishield, Serum Institute of India formulation) 2 doses.
- Moderna (Spikevax, mRNA-1273) 2 doses.
- Sinopharm, Beijing (BBIBP-CorV, BiBP vaccine, Covilo) 2 doses.
- Sinovac (CoronaVac, PiCoVacc) 2 doses.
- Bharat Biotech (Covaxin, BBV152) 2 doses.
- Novovax (Nuvaxovid, (NVX-CoV2373) 2 doses.
- Covovax (Serum Institute of India Novovax) 2 doses.
- CanSino (Convidecia, PakVac, Ad5-nCoV) 2 doses.
- Abdala (Center for Genetic Engineering and Biotechnology, CIGB-66) 2 doses.
- KoviVac (Chumakov Centre) 2 doses.
- EpiVacCorona (Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI), VECTOR) 2 doses.
- Aurora-Cov (Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI) EpiVacCorona-N) 2 doses.
- Sputnik Light (Gamaleya Research Institute of Epidemiology and Microbiology) 1 dose.
- Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology, Gam-COVID-Vac) 2 doses.
- Tukovac (Health Institutes of Turkey, ERUCOV-VAC) 2 doses.
- Soberana 02 (Instituto Finlay de Vacunas Cuba, FINLAY-FR-2, Pasteurcovac) 2 doses.
- Soberana Plus (Instituto Finlay de Vacunas Cuba, FINLAY-FR-1Am (as a 3rd dose after 2 doses of Soberana 02).
- Qazvac (Khazakstan Research Institute for Biological Safety Problems, RIBSP QazCovid-in) 2 doses.
• MVC COVID-19 vaccine (Medigen Vaccine Biologics Corporation, MVC-COV1901) 2 doses.
• KCONVAC (Minhai Biotechnology Co (Beijing), KconecaVac, Minhai COVID-19 Vaccine) 2 doses.
• Recombinant SARS-CoV-2 Vaccine (CHO Cell) (National Vaccine and Serum Institute (China), NVSI-06-08) Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08) 3 doses.
• FAKHRAVAC (Organization of Defensive Innovation and Research (Iran), MIVAC) 2 doses.
• Rasi Cov Pars (Razi Vaccine and Serum Research Institute (Iran)) 3 doses.
• COVIran Barekat (Shifa Pharmed Industrial Co (Iran) B1V1-CovIrvan) 2 doses.
• Sinopharm (Wuhan) (WIBP-CorV, Inactivated (Vero Cells) 2 doses.
• Takeda (TAK-919) (Moderna formulation) 2 doses.
• SpikoGen (Vaxine/CinnaGen Co (Australia), COVAX-19 2 doses.
• Zydus Cadila (ZyCoV-D) 3 doses.
• COVIFENZ (Medicago Inc., coVLP) 2 doses.
• VLA2001 (Valneva SE/Dynavax Technologies, VLA2101) 2 doses.


This notice comes into effect at 11.59pm on 21 March 2022.

Dated at Wellington this 18th day of March 2022.

Dr ASHLEY BLOOMFIELD, Director-General of Health.